Loading clinical trials...
Loading clinical trials...
A Phase II Trial of Tislelizumab as Consolidation Therapy in Patients With Locally Advanced Non-Small Cell Lung Cancer Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
Conditions
Interventions
Neoadjuvant chemo-immunotherapy
Bevacizumab
+2 more
Locations
1
China
Sun Yat-sen University
Guangzhou, China
Start Date
January 1, 2022
Primary Completion Date
December 30, 2024
Completion Date
December 30, 2024
Last Updated
October 30, 2024
NCT06917573
NCT01993810
NCT03154190
NCT03492801
NCT03229278
NCT03455556
Lead Sponsor
Sun Yat-sen University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions